WuXi PharmaTech (Cayman) Inc. has acquired XenoBiotic Laboratories, Inc. (XBL), a provider of bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. Financial terms were not disclosed. 
 
The acquisition expands WuXi’s Lab Testing Division in bioanalytical and DMPK/ADME services, specifically for radio-labeled compounds, expands LTD’s presence in North America, and provides access to new agricultural and animal health customers.
 
XBL has 150 employees and operates a 45,000-sq.-ft. research center in Plainsboro, NJ, and a 36,000-sq.-ft. facility in Nanjing, China. The company is FDA- and USDA-registered, New Jersey-licensed for work with radioisotopes, USDEA-licensed for conducting research with Schedule 1-5 controlled substances, and AAALAC-accredited.
 
“My colleagues and I are very excited to join WuXi, a global leader in providing drug discovery and development services to the global biopharmaceutical industry,” said Dr. Jinn Wu, president and chief executive officer of XBL, who has been appointed vice president and chief scientific officer of LTD. “We will continue to provide our services to our current clients while also offering expanded services to WuXi’s clients.”
 
“We are very pleased to have XBL join the WuXi team,” said Dr. Ge Li, chairman and chief executive officer of WuXi. “Dr. Wu has spent the past 27 years building a solid organization and reputation within the industry. This business combination is an important step in WuXi’s development of a comprehensive, integrated platform of R&D services to help our customers discover and develop drugs more efficiently and cost-effectively.”